Company: NOTV
Filing Date: 2025-05-08
Form Type: 10-Q
Source: 0001628280-25-023370
Chunk: 205

Company: Inotiv, Inc.
Filing Date: 2025-05-08
Form: 10-Q
Item: Part I, Item 2
Chunk 205
---
 status of tariffs, imported NHPs are subject to 10% tariffs and we will be working with suppliers and customers to mitigate the financial impact of these additional costs. If higher tariff rates come to pass, we also expect to work with suppliers and customers to mitigate these potential additional costs as the NHP’s are mission-critical to the safety testing of new medicines. In regards to the FDA Modernization Act 2.0, many of our acquisitions and investments have been implemented, at least in part, if not sometimes wholly, with the intent to help position us for the future. We believe our future objectives are in line with the goals outlined in the 2022, FDA Modernization Act 2.0. Examples of some of our current service offerings which we believe are in line with these goals include predictive computer software, computational toxicology, bioinformatics, proteomics, ex vivo and in vitro cell-based assays, and assays we run in human cells and tissues.

Financial Highlights During Three Months Ended March 31, 2025

•Revenue was $124,323 in the three months ended March 31, 2025, an increase of $5,288 or 4.4%, compared to $119,035 during the three months ended March 31, 2024, driven by an increase of $6,587, or 9.1%, in RMS revenue, partially offset by a $1,299, or 2.8%, decrease in DSA revenue.

•Consolidated net loss for the three months ended March 31, 2025 was $14,866, or 12.0% of total revenue, compared to consolidated net loss of $48,079, or 40.4% of total revenue, in three months ended March 31, 2024. 

•Book-to-bill ratio for the three months ended March 31, 2025 was 1.01x for the DSA services business.

•DSA backlog was $130,824 at March 31, 2025 compared to $129,916 at September 30, 2024 and $142,082 at March 31, 2024.

Financial Highlights During Six Months Ended March 31, 2025

•Revenue was $244,199 in the six months ended March 31, 2025, a decrease of $10,337 or 4.1%, compared to $254,536 during the six months ended March 31, 2024,